Baker Hughes (NASDAQ:BKR) and Kodiak Gas Services (NYSE:KGS) have finalized a multi-year strategic agreement to design and deploy custom gas turbine power solutions aimed at addressing rapid power constraints in U.S. data center and energy infrastructure markets.
Seres Therapeutics (NASDAQ:MCRB) reported positive early clinical data from a 15-patient investigator-sponsored study evaluating its microbiome candidate SER-155 in patients with immune checkpoint inhibitor-related enterocolitis.
Wrap Technologies, Inc. (NASDAQ:WRAP) announced a strategic transaction securing exclusive United States and NATO commercialization rights to Frenel Imaging’s physics-based artificial intelligence sensing technology.
Palladyne AI (NASDAQ:PDYN) reported preliminary financial results for the second quarter of fiscal 2026, with revenue increasing to approximately $5.8 million from $1 million in the same quarter of 2025.
OKYO Pharma (NASDAQ:OKYO) received positive regulatory feedback from the United States Food and Drug Administration following a Type D consultation to advance its ophthalmic candidate urcosimod into a global Phase 3 pivotal trial.
Prime Medicine (NASDAQ:PRME) secured a definitive binding arbitration victory against Beam Therapeutics regarding the clinical development rights for its Alpha-1 Antitrypsin Deficiency pipeline asset PM647.
UroGen Pharma (NASDAQ:URGN) received United States FDA clearance for its Investigational New Drug application to initiate clinical evaluations of its next-generation oncolytic virus treatment UGN-501.
Azenta (NASDAQ:AZTA) completed the sale of its B Medical Systems business to Thelema S.à r.l. on July 1, 2026.
Chemomab Therapeutics (NASDAQ:CMMB) and Scipher Medicine announced a stock-based merger agreement that will create Scipher Medicine Corporation, which is expected to trade under the ticker symbol “SCIP.”
BTQ Technologies (NASDAQ:BTQ) completed the acquisition of QPerfect, a France-based quantum software company, strengthening its Quantum Ready infrastructure platform.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
